Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
Type:
Grant
Filed:
January 20, 2023
Date of Patent:
January 30, 2024
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
Abstract: The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
January 23, 2024
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Sylvie Laquerre, Matthew Lorenzi, Sheri Moores
Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
January 9, 2024
Assignee:
Janssen Biotech, Inc.
Inventors:
Philip Cooper, Robin Ernst, Rajkumar Ganesan, Colleen Kane, Michael Russell, Sanjaya Singh, Sathyadevi Venkataramani, Sheng-Jiun Wu
Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
Abstract: Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
December 19, 2023
Assignees:
Janssen Biotech, Inc., Protagonist Therapeutics, Inc.
Inventors:
Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari
Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
Type:
Grant
Filed:
January 20, 2021
Date of Patent:
December 5, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
Abstract: The invention provides antigen binding domains that bind human leukocyte antigen G (HLA-G) protein comprising the antigen binding domains that bind HLA-G, polynucleotides encoding them, vectors, host cells, methods of making and using them.
Type:
Grant
Filed:
July 29, 2021
Date of Patent:
November 28, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Natasa Obermajer, Adam Zwolak, Sylvie Laquerre, Dirk Brehmer, Desiree De Lange, Julien Häsler, Shana Versmissen, Theodore D. Petley, Kelly van de Ven, Fang Yi, Sanjaya Singh, Rajkumar Ganesan
Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.
Type:
Application
Filed:
March 17, 2023
Publication date:
November 23, 2023
Applicant:
JANSSEN BIOTECH, INC.
Inventors:
Sanjaya SINGH, Rajkumar GANESAN, Jun CHEN, Iqbal S. GREWAL
Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
October 24, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
October 10, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
Abstract: The disclosure provided herein relates to monospecific and multispecific antibodies, that bind CEACAM1 and optionally CEACAM5 and/or CEACAM6, and methods of producing and using the described antibodies.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
September 19, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Wendell Lamar B Blackwell, Douglas V. Dolfi, Cassandra L. Lowenstein, Raluca I. Verona
Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.
Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 × 105 to 5.0 × 106 of CAR-T cells per kilogram of the subject’s mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
September 5, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.